CVS Health Corp.

1 day ago · 247wallst.com

A Chicago lawyer who survived the Pacific Theater came home, put a modest sum into his neighborhood drugstore, and never touched it again. What he eventually did with the fortune he quietly built stunned everyone who knew him.

3 days ago · zacks.com

Besides Wall Street's top-and-bottom-line estimates for CVS Health (CVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

5 days ago · seekingalpha.com

CVS Health has executed a robust turnaround, prompting an upgrade from hold to buy with a $115 price target. Accelerating earnings, raised guidance, improved margins, and reduced leverage underpin a strengthened long-term investment case for CVS. Dividend safety is enhanced by strong free cash flow and a low payout ratio, supporting income investors amid potential volatility.

5 days ago · zacks.com

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

5 days ago · zacks.com

CVS Health (CVS) closed the most recent trading day at $91.13, moving 1.51% from the previous trading session.

5 days ago · prnewswire.com

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

6 days ago · businesswire.com

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS). On August 2, 2023, the Company announced its financial results for the quarter ended June 30, 2023, disclosing that it was revising its diluted earnings-per-share ("EPS") guidance range to $6.53 to $6.75 fr.

6 days ago · fool.com

After a couple of challenging years, CVS Health has been generating some improved numbers in 2026. The company is expecting a significant improvement on the bottom line this year.

7 days ago · zacks.com

CVS' third-quarter 2026 results face mixed segment trends, with Aetna's margin recovery and digital investments offering support amid persistent 340B pressures and membership declines.

10 days ago · zacks.com

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.